成人无码高潮av在线观看_欧洲极品少妇_夂久亚州精华国产精华华液_在线观看亚洲AV每日更新无码_亚洲国产精品无码久久一线_亚洲精品区午夜亚洲精品区

美國ChemoCentryx
ChemoCentryx公司正在開發(fā)用于治療自身免疫性疾病、炎性疾病和腫瘤的口服藥物，這些藥物主要針對趨化因子和化學誘導系統(tǒng)。
ChemoCentryx公司最領先的藥物是Traficet-EN，目前處于治療克羅恩病的Ⅲ期臨床試驗階段和乳糜瀉的Ⅱ期臨床階段以及潰瘍性結腸炎的I期臨床研究階段。另外，該公司還有一些藥物處于I期臨床階段，分別是治療胃腸道疾病的CCX025、治療脈管狹窄和多發(fā)性硬化癥的CCX140以及治療類風濕性關節(jié)炎的CCX354。



ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds.